| (210) | Number of the EPO application | 20709101 |
| (220) | Filing date of the EPO application | 2020.02.06 |
| (80) | EPO patent specification publication (B) | EPB nr. 14/2023, 2023.04.05 |
| (110) | EPO patent number | 3921327 |
| (21) | Number of the application | e 2021 1196 |
| (71) | Name(s) of applicant(s), code of the country | Ardelyx, Inc., US; |
| (72) | Name(s) of inventor(s), code of the country | DRAGOLI Dean, US;
LUEHR Gary, US;
CHEN Tao, US;
LEWIS Jason, US;
LEADBETTER Michael, US; |
| (73) | Name(s) of owner(s), code of the country | Ardelyx, Inc., US; |
| (54) | Title of the invention | GLYCYRRHETINIC ACID DERIVATIVES FOR USE IN TREATING HYPERKALEMIA |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | C07J 63/00 (2006.01.01); A61K 31/56 (2006.01.01); A61P 5/40 (2006.01.01) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2021.12.31 |
| (30) | Priority | 201962802210 P, 2019.02.07, US |
| (86) | International application | PCT/US2020/017077, 2020.02.06 |
| (87) | International publication | WO 2020/163642, 2020.08.13 |